SKYE Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Skye Bioscience, Inc.

Core Viewpoint - A class action has been filed against Skye Bioscience, Inc. for allegedly misleading investors about the effectiveness and prospects of its lead drug candidate, nimacimab [1][2]. Group 1: Company Overview - Skye Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases [1]. - The lead product candidate of the company is nimacimab [1]. Group 2: Allegations and Impact - The complaint alleges that during the class period, Skye failed to disclose that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - On October 6, 2025, Skye announced that the nimacimab monotherapy did not achieve the primary endpoint of weight loss compared to placebo, resulting in a stock price drop of $2.85 per share, or 60%, closing at $1.90 per share [3]. Group 3: Legal Proceedings - Shareholders wishing to serve as lead plaintiff in the class action must submit their papers by January 16, 2026 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].